Bacterial Conjunctivitis Clinical Trial
Official title:
AL-15469A for the Treatment of Bacterial Conjunctivitis
| NCT number | NCT00331916 |
| Other study ID # | C-04-38 |
| Secondary ID | |
| Status | Completed |
| Phase | Phase 3 |
| First received | May 30, 2006 |
| Last updated | September 25, 2009 |
| Start date | November 2005 |
| Verified date | September 2009 |
| Source | Alcon Research |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | United States: Food and Drug Administration |
| Study type | Interventional |
The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.
| Status | Completed |
| Enrollment | 600 |
| Est. completion date | |
| Est. primary completion date | May 2007 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 1 Month and older |
| Eligibility |
Inclusion Criteria: - Signs & Symptoms of conjunctivitis Exclusion Criteria: - Under 1 mo. age |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Country | Name | City | State |
|---|---|---|---|
| United States | US | Fort Worth | Texas |
| Lead Sponsor | Collaborator |
|---|---|
| Alcon Research |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Clinical cure and microbiological success | |||
| Secondary | Individual signs and symptoms of bacterial conjunctivitis at each visit |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00565123 -
Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00972777 -
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
|
Phase 2/Phase 3 | |
| Completed |
NCT00759148 -
Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
| Completed |
NCT00798577 -
Study of the Progression of Bacterial Conjunctivitis Symptoms Upon Antibiotic Treatment
|
Phase 4 | |
| Completed |
NCT02432807 -
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
|
Phase 3 | |
| Completed |
NCT01573910 -
An Evaluation of the Safety and Efficacy of Moxifloxacin Ophthalmic Solution 0.5% ((VIGAMOX®) Versus Ofloxacin Ophthalmic Solution 0.3% in the Treatment of Bacterial Conjunctivitis in Chinese Patients
|
Phase 3 | |
| Terminated |
NCT01330355 -
Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis
|
Phase 3 | |
| Completed |
NCT00332293 -
AL-15469A for the Treatment of Bacterial Conjunctivitis
|
Phase 3 | |
| Completed |
NCT03004924 -
Treatment of Bacterial Conjunctivitis With SHP640 Compared to PVP-Iodine and Placebo
|
Phase 3 | |
| Completed |
NCT02980523 -
Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)
|
Phase 2 | |
| Completed |
NCT01877694 -
Efficacy and Safety of Auriclosene (NVC-422) in the Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
| Completed |
NCT01175590 -
Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle
|
Phase 3 | |
| Completed |
NCT00464438 -
A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis
|
Phase 4 | |
| Completed |
NCT00312338 -
Topical Treatment of Bacterial Conjunctivitis and Its Effect on Microbial Flora
|
Phase 4 | |
| Recruiting |
NCT03235141 -
Local Pharmacokinetics of Azithromycin Eye Drops in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT00105469 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
|
Phase 3 | |
| Completed |
NCT00105534 -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Vehicle for Bacterial Conjunctivitis (C-01-401-003)
|
Phase 3 | |
| Recruiting |
NCT06363292 -
Study to Evaluate the Safety and Tolerability of PRO-231 Ophthalmic Solution Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects.
|
Phase 1 | |
| Withdrawn |
NCT01238783 -
Safety and Efficacy of AL-15469A 0.5% / AL-6515 0.3% Ophthalmic Suspension for Treatment of Bacterial Conjunctivitis
|
Phase 2 | |
| Terminated |
NCT01740388 -
Clinical and Microbial Efficacy of Besifloxacin Ophthalmic Suspension, 0.6% in the Treatment of Bacterial Conjunctivitis
|
Phase 3 |